The 2018 Cholesterol Clinical Practice Guidelines were released and endorsed by multiple associations including the National Lipid Association, American Diabetes Association, American Pharmacists Association, American Society for Preventive Cardiology, and Preventive Cardiovascular Nurses Association, to name a few. 1 Grundy S.M. Stone N.J. Bailey A.L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA /ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018 Nov 10; ([Epub ahead of print]) Google Scholar Since the prior guideline and addendums, studies have been published showing the benefit of nonstatin lipid-lowering agents. Ezetimibe demonstrated atherosclerotic cardiovascular disease (ASCVD) morbidity reduction (specifically myocardial infarction and stroke) in patients with acute coronary syndrome when added to a moderate-intensity statin, 2 Cannon C.P. Blazing M.A. Giugliano R.P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 375: 2387-2397 Google Scholar and both evolocumab 3 Sabatine M.S. Giugliano R.P. Keech A.C. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713-1722 Crossref PubMed Scopus (3169) Google Scholar and alirocumab 4 Odyssey Outcomes Investigators and CommitteeThe Odyssey Outcome Trial Topline results: alirocumab in patients’ after acute coronary syndrome. https://accscientificsession.acc.org/features/2018/03/video-sanofi-regeneronDate: 2018 Date accessed: November 16, 2018 Google Scholar have shown further reduction of ASCVD risk in secondary prevention. Roda Plakogiannis, BS, PharmD, BCPS, CLS, FNLA, is an associate professor of pharmacy practice at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University in Brooklyn, NY. Department Editor Timothy Nguyen, PharmD, BCPS, CCP, FASCP, would like to hear your ideas for future columns at .